NICE fails to en­dorse Roche's Tecen­triq for breast can­cer; Eli­cio clos­es fi­nanc­ing round with $33M

→ UK’s cost-ef­fec­tive­ness watch­dog NICE is not back­ing Roche‘s PD-L1 check­point in­hibitor Tecen­triq (known chem­i­cal­ly as ate­zolizum­ab), in an­oth­er blow to the Swiss drug­mak­er who re­vealed the drug wasn’t strong enough to score ap­proval in blad­der can­cer at the ES­MO con­fer­ence last week­end. NICE’s draft guid­ance, how­ev­er, per­tains to the im­munother­a­py’s use in ad­vanced breast can­cer in com­bi­na­tion with the chemother­a­py nab-pa­cli­tax­el.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER